Claris Bio Appoints New CEO, CCO, and Board Chair

Company Claris Bio Event Type Leadership Transition (CEO, CCO, and Board Chair Appointments) Modality Ocular-surface / corneal repair therapeutic (commercial franchise context) Platform CSB-001 pivotal development program Indication Limbal stem-cell deficiency Summary Claris Bio appointed Stephen Brady president and CEO, Brian Baum chief commercial officer,…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Weekly Market Insight

MeiraGTx – $400M Oberland Strategic Financing for Late-Stage Gene Therapy Programs
Beeline Therapeutics – $300M Launch
Repligen Buys BioLife for $1.5 Billion
Nurix + Roche; Global BTK Degrader Collaboration